Your slide has been added to the download list.
Treat-to-target recommendations for SpA 2017
Category:
- Outcome Measures
Order number: 500
Choosing a target – DAPSA
Category:
- Outcome Measures
Order number: 510
Choosing a target – MDA
Category:
- Outcome Measures
Order number: 520
DAPSA vs MDA
Category:
- Outcome Measures
Order number: 530
ACR20 vs MDA
Category:
- Outcome Measures
Order number: 540
Summary of treatment modalities
Category:
- PsA Treatments
Order number: 10
PsA pharmacotherapy considerations
Category:
- PsA Treatments
Order number: 20
Pathogenesis of psoriatic arthritis
Category:
- PsA Treatments
Order number: 30
EULAR: Treatment Recommendations for PsA
Category:
- PsA Treatments
Order number: 40
GRAPPA Treatment Recommendations 2021 Update
Category:
- PsA Treatments
Order number: 50
PsA treatment overarching principles
Category:
- PsA Treatments
Order number: 60
PsA treatment overarching principles
Category:
- PsA Treatments
Order number: 70
GRAPPA PsA Tx Recommendations 2021
Category:
- PsA Treatments
Order number: 80
Traditional therapies for PsA
Category:
- PsA Treatments
Order number: 90
MTX vs ETN: the SEAM trial
Category:
- PsA Treatments
Order number: 100
Role of TNF signaling in PsA pathogenesis
Category:
- PsA Treatments
Order number: 110
TNFi therapies in PsA: ACR responses
Category:
- PsA Treatments
Order number: 120
Ustekinumab: p40 inhibitor
Category:
- PsA Treatments
Order number: 130
Ustekinumab – PSUMMIT 1
Category:
- PsA Treatments
Order number: 140
Ustekinumab – PSUMMIT 2
Category:
- PsA Treatments
Order number: 150
Role of IL-17 signaling in joint inflammation and matrix destruction
Category:
- PsA Treatments
Order number: 160
Secukinumab – Efficacy in Anti–TNF-naïve and Anti–TNF-IR Patients (FUTURE 2)
Category:
- PsA Treatments
Order number: 170
Secukinumab – Efficacy in H2H vs ADA (EXCEED)
Category:
- PsA Treatments
Order number: 180
Ixekizumab – Bio-Naïve PsA (SPIRIT-P1)
Category:
- PsA Treatments
Order number: 190
Ixekizumab vs Adalimumab (SPIRIT H2H)
Category:
- PsA Treatments
Order number: 200
IL-23: Mechanisms of action
Category:
- PsA Treatments
Order number: 210
Guselkumab – DISCOVER 1 & DISCOVER 2
Category:
- PsA Treatments
Order number: 220
Guselkumab – COSMOS
Category:
- PsA Treatments
Order number: 230
Risankizumab – KEEPsAKE 1+2
Category:
- PsA Treatments
Order number: 240
CTLA4-Ig: Mechanisms of action
Category:
- PsA Treatments
Order number: 250
Abatacept
Category:
- PsA Treatments
Order number: 260
Targeted Synthetic DMARDs: Intracellular signaling pathways in PsA
Category:
- PsA Treatments
Order number: 270
Tofacitinib – TNF-IR
Category:
- PsA Treatments
Order number: 280
PDE4 inhibitor: Apremilast (PALACE 1)
Category:
- PsA Treatments
Order number: 290
Upadacitinib – SELECT-PsA-1
Category:
- PsA Treatments
Order number: 300
Enthesitis
Category:
- PsA Treatments
Order number: 310
TNFi – SEAM-PsA & GO-DACT
Category:
- PsA Treatments
Order number: 320
Ustekinumab – PSUMMIT I and PSUMMIT II
Category:
- PsA Treatments
Order number: 330
Secukinumab: Enthesitis
Category:
- PsA Treatments
Order number: 340
Ixekizumab – Enthesitis
Category:
- PsA Treatments
Order number: 350
Guselkumab – DISCOVER 1 + 2
Category:
- PsA Treatments
Order number: 360
Risankizumab – KEEPsAKE 1+2
Category:
- PsA Treatments
Order number: 370
JAK inhibitors – Enthesitis (OPAL & SELECT-PsA 1)
Category:
- PsA Treatments
Order number: 380
Apremilast – Enthesitis (PALACE 1)
Category:
- PsA Treatments
Order number: 390
Dactylitis
Category:
- PsA Treatments
Order number: 400